Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Ticker
- $JNJ
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 138,200
- Headquarters
- New Brunswick, United States
- Website
- www.jnj.com
JNJ Metrics
BasicAdvanced
$626bn
30.12
$8.63
0.23
$5.24
2.06%
Price and volume
Market cap
$626bn
Beta
0.23
52-week high
$274.90
52-week low
$171.81
Average daily volume
7.8m
Dividend rate
$5.24
Financial strength
Current ratio
1.089
Quick ratio
0.725
Long term debt to equity
43.949
Total debt to equity
67.73
Dividend payout ratio (TTM)
59.99%
Interest coverage (TTM)
25.13%
Profitability
EBITDA (TTM)
34,840
Gross margin (TTM)
68.14%
Net profit margin (TTM)
21.48%
Operating margin (TTM)
27.69%
Effective tax rate (TTM)
16.51%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
8.59%
Return on equity (TTM)
25.74%
Valuation
Price to earnings (TTM)
30.115
Price to revenue (TTM)
6.414
Price to book
7.36
Price to tangible book (TTM)
-53.31
Price to free cash flow (TTM)
28.621
Free cash flow yield (TTM)
3.49%
Free cash flow per share (TTM)
9.077
Dividend yield (TTM)
2.02%
Forward dividend yield
2.06%
Growth
Revenue change (TTM)
8.06%
Earnings per share change (TTM)
-7.58%
3-year revenue growth (CAGR)
5.95%
10-year revenue growth (CAGR)
3.29%
3-year earnings per share growth (CAGR)
20.48%
10-year earnings per share growth (CAGR)
4.86%
3-year dividend per share growth (CAGR)
4.59%
10-year dividend per share growth (CAGR)
5.56%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire3 days ago
Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
Business Wire1 week ago
Johnson & Johnson's OTTAVA Robotic Surgery System Targets Long-Term Growth
MarketBeat1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.